|
On-study age—years
| |
|
Median
|
57
|
|
Range
|
25—81
|
|
Sex-no. (%)
| |
|
Female
|
10 (56)
|
|
Male
|
8 (44)
|
|
Ethnicity-no. (%)
| |
|
Non-hispanic white
|
7 (39)
|
|
Non-hispanic African-American
|
6 (33)
|
|
Other
|
5 (28)
|
|
Primary site (%)*
| |
|
Left colon/rectum
|
11 (61)
|
|
Right colon
|
6 (33)
|
|
Histologic grade
| |
|
Well differentiated
|
0 (0)
|
|
Moderately differentiated
|
14 (78)
|
|
Poorly differentiated
|
2 (11)
|
|
Unknown
|
2 (11)
|
|
Time from metastatic diagnosis-months
| |
|
Median
|
32
|
|
Range
|
4—172
|
|
Metastatic site (%)
| |
|
Liver only
|
4
|
|
Lymph nodes only
|
1
|
|
Bladder only
|
1
|
|
Multiple sites
|
12
|
|
Exposure to prior therapies (%)
| |
|
Fluoropyrimidine
|
18 (94)
|
|
Oxaliplatin
|
17 (94)
|
|
Irinotecan
|
17 (94)
|
|
Anti-VEGF
|
17 (94)
|
|
Anti-EGFR
|
8 (44)
|
|
KRAS mutation status
| |
|
Wild-type
|
7
|
|
Mutant
|
9
|
|
Unknown
|
2
|
|
Microsatellite Instability/Mismatch Repair Status
| |
|
MSI-H/dMMR
|
1
|
|
MSS/pMMR
|
12
|
|
Unknown
|
5
|
